Oncorus Inc (NASDAQ:ONCR) has signed an exclusive licensing agreement with Gaeta Therapeutics Ltd, related to the use of locally delivered Interleukin-12 (IL-12)…
Oncorus (NASDAQ:ONCR) reported quarterly losses of $(0.65) per share. This is a 97.01 percent increase over losses of $(21.73) per share from the same period last year.